MedTrace Logo

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124552 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2014-01-30

No results posted yet for this study

Summary

The purpose of this study is to find out if an investigational drug, called RT001 Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet wrinkles.

Conditions

  • Lateral Canthal Lines
  • Crow's Feet
  • Facial Wrinkles

Interventions

DRUG

RT001 Botulinum toxin type A (Dose A)

RT001 Botulinum Toxin Type A (Dose A)

DRUG

RT001 Botulinum Toxin Type A (Dose B)

RT001 Botulinum Toxin Type A (Dose B)

OTHER

Vehicle

Vehicle Control

DRUG

Placebo

Placebo Comparator

Sponsors & Collaborators

  • Revance Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01124552 on ClinicalTrials.gov